Incretin mimetics (GLP-1RAs) were convinced significantly of reducing the major cardiovascular adverse events, and recommended as the first-line medicine in type 2 diabetes mellitus patients with cardiovascular risk factors. This evidence concerns the gene GCG and type 2 diabetes mellitus.